DJ US Pharmaceuticals Ishares (IHE) 178.85 $IHE iShares

New Post Public Reply Private Reply Replies (0) Message Board

Mar 21, 2015 at 10:37 PM

DJ US Pharmaceuticals Ishares (IHE) 178.85 $IHE

iShares Dow Jones US Pharmaceuticals Index Fund Shares Up 12.4% Since SmarTrend's Buy Recommendation (IHE)
Comtex SmarTrend(R) - Tue Mar 17, 9:39AM CDT
SmarTrend identified an Uptrend for iShares Dow Jones US Pharmaceuticals Index Fund (NYSE:IHE) on January 8th, 2015 at $155.64. In approximately 2 months, iShares Dow Jones US Pharmaceuticals Index Fund has returned 12.44% as of today's recent price of $174.99.
IHE: 178.85 (-0.32)

12 Best Biotech and Health Care ETFs to Add to Your Portfolio
at The Street - Thu Mar 12, 9:49AM CDT
Biotech and health care are two of the hottest sectors in which to invest. TheStreet compiled a list of the best-rated ETFs tracking the two sectors.
IHE: 178.85 (-0.32), IHF: 134.41 (+0.34), XHE: 95.03 (-0.32), IYH: 159.39 (+0.86), XHS: 125.51 (+0.62), GRX: 11.23 (+0.07), FHLC: 36.29 (-0.04), IHI: 120.98 (+0.18), IXJ: 110.64 (+1.24), VHT: 139.38 (+0.70), FXH: 68.50 (+0.07), XLV: 74.90 (+0.33)

Pharma ETFs to Soar No Matter Who Wins Salix - ETF News And Commentary
Sweta Killa - Zacks Investment Research - Thu Mar 12, 9:15AM CDT
The Salix takeover war is pushing pharma ETFs higher.
IHE: 178.85 (-0.32), ENDP: 92.37 (+0.89), VRX: 204.26 (+2.17), PJP: 80.41 (+0.33), SLXP: 172.80 (+0.26), XPH: 130.00 (-1.39)

3 Pharmaceutical Stocks Set for Massive Earnings Growth in 2015 - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Mon Mar 02, 12:20PM CST
These pharma stocks have seen rising earnings estimates lately and could be poised for growth in 2015.
IHE: 178.85 (-0.32), LCI: 68.57 (-0.32), SCMP: 17.89 (-0.67), BLRX: 2.06 (+0.03)

Pfizer Set to Acquire Hospira: Healthcare ETFs in Focus - ETF News And Commentary
Sweta Killa - Zacks Investment Research - Fri Feb 06, 9:00AM CST
Healthcare ETFs are worth a look given that Pfizer will buy Hospira.
IHE: 178.85 (-0.32), PPH: 71.99 (+0.73), IYH: 159.39 (+0.86), PFE: 34.25 (+0.10), HSP: 87.64 (-0.06), XLV: 74.90 (+0.33)

Big Pharma Weak Guidance Put These ETFs in Focus - ETF News And Commentary
Sweta Killa - Zacks Investment Research - Thu Feb 05, 10:00AM CST
How pharma ETFs are looking after the string of earnings beat and disappointing guidance?
IHE: 178.85 (-0.32), JNJ: 102.40 (+0.71), PPH: 71.99 (+0.73), PJP: 80.41 (+0.33), MRK: 58.58 (+0.37), PFE: 34.25 (+0.10), LLY: 76.12 (+1.90), BMY: 67.76 (-0.56)

Can Pharma ETFs Continue Their Uptrend In 2015?
Zacks Funds - Seeking Alpha - Fri Jan 09, 4:37PM CST
The pharmaceutical sector, which had been witnessing several tax inversion deals over the last few months, is not likely to go down this route given the Sep 2014 notice issued by the U.S. Department of the Treasury. New rules imposed by the Treasury...
IHE: 178.85 (-0.32), PPH: 71.99 (+0.73), PJP: 80.41 (+0.33), XPH: 130.00 (-1.39)

Can Pharma ETFs Continue their Uptrend in 2015? - ETF News And Commentary
Zacks Equity Research - ZACKS - Fri Jan 09, 11:00AM CST
Several factors suggest that Pharma ETFs may continue their strong performance this year as well.
IHE: 178.85 (-0.32), PPH: 71.99 (+0.73), PJP: 80.41 (+0.33), XPH: 130.00 (-1.39)

Where Do Cures Reside? The Answer Is In Regenerative Medicine
Life Sciences Report - Seeking Alpha - Fri Jan 09, 7:37AM CST
The practice of medicine is being transformed. The journey has been arduous, but revolutionary stem cell, gene and immunocellular therapies are rapidly moving toward pivotal milestones-and investors in the space should strap in for a rewarding joy...
BBP: 32.37 (-0.23), RXL: 149.91 (+1.63), XBI: 233.86 (-4.12), IHE: 178.85 (-0.32), IHF: 134.41 (+0.34), PPH: 71.99 (+0.73), XHE: 95.03 (-0.32), BBC: 35.07 (-0.58), PTH: 63.31 (-0.61), BBH: 138.45 (+0.69), FHLC: 36.29 (-0.04), IHI: 120.98 (+0.18), CURE: 161.18 (+3.49), FXH: 68.50 (+0.07), VHT: 139.38 (+0.70), RYH: 159.00 (+0.69), PBE: 58.47 (-0.79), IYH: 159.39 (+0.86), FBT: 125.71 (-0.27), XHS: 125.51 (+0.62), XPH: 130.00 (-1.39), XLV: 74.90 (+0.33), SBIO: 31.04 (-0.89), PSCH: 68.93 (+0.03), PJP: 80.41 (+0.33), RXD: 12.24 (-0.14)

Kyle Bass's Assault On Pharma Patents
IP Hawk - at Seeking Alpha - Thu Jan 08, 12:25PM CST

BBP: 32.37 (-0.23), RXL: 149.91 (+1.63), XBI: 233.86 (-4.12), IBB: 366.52 (+1.27), IHE: 178.85 (-0.32), IHF: 134.41 (+0.34), BBC: 35.07 (-0.58), PPH: 71.99 (+0.73), XHE: 95.03 (-0.32), PTH: 63.31 (-0.61), BBH: 138.45 (+0.69), FHLC: 36.29 (-0.04), IHI: 120.98 (+0.18), CURE: 161.18 (+3.49), FXH: 68.50 (+0.07), VHT: 139.38 (+0.70), RYH: 159.00 (+0.69), PBE: 58.47 (-0.79), IYH: 159.39 (+0.86), FBT: 125.71 (-0.27), XHS: 125.51 (+0.62), XPH: 130.00 (-1.39), XLV: 74.90 (+0.33), SBIO: 31.04 (-0.89), PSCH: 68.93 (+0.03), PJP: 80.41 (+0.33), RXD: 12.24 (-0.14)

Pharma ETFs In Focus On Allergan Takeover Deal
Zacks Funds - at Seeking Alpha - Sat Nov 22, 9:10PM CST
The health care space is witnessing 2014 as another banner year thanks to encouraging industry trends, solid corporate earnings and huge levels of merger and acquisition activities. The sector is clearly leading the broad market rally and this trend...
IHE: 178.85 (-0.32), AGN: 240.22 (+2.88), PPH: 71.99 (+0.73), ACT: 317.06 (+2.65), XPH: 130.00 (-1.39)

Pharma ETFs in Focus on Allergan Takeover Deal - ETF News And Commentary
Sweta Killa - ZACKS - Tue Nov 18, 12:00PM CST
Pharma ETFs could get further boost from Actavis and Allergan merger deal in the coming days.
IHE: 178.85 (-0.32), AGN: 240.22 (+2.88), VRX: 204.26 (+2.17), PPH: 71.99 (+0.73), ACT: 317.06 (+2.65), XPH: 130.00 (-1.39)

Big Pharma Solid Q3 Earnings Put These ETFs in Focus - ETF News And Commentary
Sweta Killa - ZACKS - Thu Oct 30, 1:00PM CDT
Pharma ETFs have been surging over the past one week buoyed by solid earnings from big industry players.
IHE: 178.85 (-0.32), JNJ: 102.40 (+0.71), PPH: 71.99 (+0.73), PJP: 80.41 (+0.33), MRK: 58.58 (+0.37), LLY: 76.12 (+1.90), BMY: 67.76 (-0.56)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Boliden's Q3 2026 Results: What's on the Horizon?

Boliden Ready to Reveal Q3 Numbers Mark it down, folks. Thursday, October 29, 2026, is the day when Boliden's big wigs will step up to the plate and lay their cards on the table about the company's performance over the last quarter. If you've got any skin in this mining powerhouse, you'll want a front-row seat—or at least a virtual one if you're dialing in from...

DIFF Eyewear Opens First Flagship Store in Charleston

DIFF Eyewear: From Clicks to Bricks in Charleston Here's a tale of a brand shaking things up, jumping from the digital stratosphere right into solid ground. DIFF Eyewear has officially planted its flag in Charleston, SC, marking a bold transition from being an exclusively online player to real-world retail. October 10th rang in their first brick-and-mortar store on...

2026 Leica Oskar Barnack Awards Spotlight Global Talent

Winners Redefine Photography's Boundaries in 2026 Photographers are like modern-day storytellers, freezing moments in time and weaving visual narratives that provoke thought—or at least that's what the folks behind the Leica Oskar Barnack Award (LOBA) seem to believe. This year's ceremony upped the ante, not just handing out glittering prizes and shiny cameras, but...

ODL’s Impact Door System Wins 2026 Editors' Pick

Award-Winning Entry: ODL's Latest Triumph In a world where first impressions count, ODL, Inc. sure knows how to leave a mark. Their Impact Rated Fiberglass Entry System with Keystone Frame Technology snagged a notable spot in the 2026 Best of Products Awards by Architect's Newspaper. Let me tell you, in the building biz, accolades like these are no small potatoes. To get...

Zenni and Chase Stokes Foster Student Wellbeing in NYC

Picture this: near 300 high schoolers milling around, glancing through shiny new glasses from the Zenni x Chase Stokes collection. In the heart of New York City, these kids are getting a double-dose of care that's all too rare—free vision screenings paired with mental health support. It's the kind of collaboration that shows you what's possible when a company, an actor,...

Mastering Packaging Costs: Beyond the Box Price

Peeling Back the Layers of Packaging Costs Packaging's a bit like an onion—every layer you peel back reveals another cost you didn’t see at first glance. Folks in the know, like Kyle Reger of Jamestown Container Companies, are flipping the script on how we approach packaging expenses. It's not just about snagging the cheapest box on the shelf anymore. There's a whole...

Greenberg Traurig Nabs Major Award for Sukuk Deal

Legal brands winning awards might seem like just another day in the office, but when a firm like Greenberg Traurig snags the Impact Deal of the Year at the IFLR Middle East Awards, it deserves more than just a shrug. We're talking about a serious feather in the cap for their Capital Markets team, who played a key role in launching Binghatti's hefty USD 1.5 billion Sukuk...

Duke Energy Braces for Isaias: Key Prep Steps Ahead

Brace Yourself: Duke Energy Gears Up for Isaias In the ever-unpredictable game of Mother Nature versus infrastructure, Duke Energy is stepping into the ring once more, readying to tackle potential outages across the Carolinas as Hurricane Isaias edges near. Listen, if there's one thing I've learned over years of watching these weather events unfold on the stock ticker and...

Helio Genomics Shakes Up Liver Cancer Detection Strategy

Rethinking Liver Cancer Detection with HelioLiver Sometimes you stumble upon a tech piece that might genuinely shake up the game. Helio Genomics just poured some serious intel at the San Antonio Liver Cancer Symposium, showcasing how their HelioLiver Dx might outgun traditional scans in sniffing out hepatocellular carcinoma (HCC). They threw down four studies revealing...

Bill Evans Enhances Gateway's Wealth Management Expertise

Welcome Aboard, Bill Evans Some days the financial world throws a gem your way, something worth more than a rat-race racehorse in a shattered stock rally. Meet Bill Evans, a seasoned professional stepping into the vibrant arena of Gateway Financial Partners. He’s put in 29 years around the investment block, and now he’s parking himself in Glastonbury, Connecticut, set...